CLSA today applauded Gov. Jerry Brown for signing Senate Bill 1121, legislation that helps protect clinical trials conducted in California, which are the lifeblood of new and innovative medicines to treat patients in need. SB 1121 was approved by the California Legislature earlier this year and signed into law yesterday, Sept. 24, by Brown.
CLSA recently spoke with STAT News regarding SB 1121, critical legislation on Gov. Brown’s desk that will preserve California patient access to clinical trials and allow innovative research to continue.
Today, CLSA announced the recipients of the 2018 Pantheon DiNA™ Awards. This prestigious and long-running awards program, now in its 15th year, brings together nearly 1,000 industry pioneers to recognize the achievements of those dedicated to advancing California’s life sciences community.
Two major bills of interest to CLSA have been presented to Governor Brown for his signing or veto: include SB 212 (Jackson) and SB 1121 (Dodd). A third key bill of interest to CLSA, AB 2167 (Chau), died in the Senate during the final week of the legislative session.
California Life Sciences Association (CLSA) today urged Governor Jerry Brown to sign Senate Bill 1121, legislation that helps protect clinical trials conducted in California, which are the lifeblood of new and innovative medicines to treat patients in need. SB 1121 was approved by the California Legislature earlier this year and awaits action by Governor Brown, who has until Sept. 30 to sign or veto the legislation.
Did you miss CLSA’s Evening With Thought Leaders event in August? Check out this article from the San Diego Business Journal to learn more about the digital health symposium.
CLSA President & CEO Sara Radcliffe was recently quoted in the San Francisco Business Times commenting on a new report that shows California’s life sciences sector has the most biotech R&D jobs in the nation.
Assembly Bill 375, the California Consumer Privacy Act, will require companies that store large amounts of data, such as Google, Facebook, Twitter, and others, to disclose what kinds of data they collect, and give consumers more control over how that data is shared.
The California Life Sciences Association (CLSA) joined a coalition, which includes fellow life sciences trade associations, providers, insurers, and a number of other key stakeholders, to address the concerns related to HIPAA preemption and clinical trials data in the recently enacted AB 375, “The California Consumer Privacy Act of 2018” (“Privacy Act”), which will become effective January 1, 2020.
CLSA’s federal government relations team provides an update on the outlook for key federal life sciences legislation likely to be addressed this year in Congress.